Novartis Says Adverse Gleevec Ruling Would Impact Outlook For India
This article was originally published in PharmAsia News
Executive Summary
As India’s Supreme Court prepares to deliver a landmark verdict next week on the patentability of Gleevec, Novartis prepares for stormy weather.
You may also be interested in...
Supreme Court Judge Recused From Glivec Patent Case In India
MUMBAI - A strongly worded letter of appeal signed by prominent IP lawyers and health activists to India's minister of law and Justice Salman Khurshid led to the surprise recusal of Supreme Court Judge Dalveer Bhandari from the controversial and long-pending Glivec (imatinib) patentability case in India
Novartis Suffers Setback As Indian Patent Appeals Board Strikes Down Glivec Patent
MUMBAI - Hopes for Novartis to obtain a product patent for its chronic myeloid leukemia drug Gleevec (imatinib) were dashed after India's Intellectual Property Appellate Board ruled that Novartis' patent application covering the medicine's beta-crystalline version is not patentable because it failed to satisfy the requirements under Section 3(d) of the India Patents Act
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.